
Nikolaos Kanellakis
Articles
-
Apr 1, 2024 |
nature.com | Pablo F. Céspedes |Uzi Gileadi |Zhu Liang |Fei Gao |Nikolaos Kanellakis |Yi-Ling Chen | +7 more
AbstractCancer remains one of the leading causes of mortality worldwide, leading to increased interest in utilizing immunotherapy strategies for better cancer treatments. In the past decade, CD103+ T cells have been associated with better clinical prognosis in patients with cancer. However, the specific immune mechanisms contributing toward CD103-mediated protective immunity remain unclear.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →